Erratum: Treatment, rationale, and study design of TALISMAN study: A randomized phase II open-label study of second-line erlotinib versus intermittent erlotinib dosing with docetaxel in the treatment of former-smoker men affected by recurrent squamous non-small-cell lung cancer (Clinical Lung Cancer (2011) 12 (70-73) DOI:10.3816/CLC.2011.n.010);Treatment, rationale, and study design of TALISMAN study: A randomized phase II open-label study of second-line erlotinib versus intermittent erlotinib dosing with docetaxel in the treatment of former-smoker men affected by recurrent squamous non-small-cell lung cancer

Clinical Lung Cancer

Volumn 12, Issue 1, 2011, Pages 70-73

  Gridelli, Cesare ^a   Rossi, Antonio ^a   Venturino, Paola ^b   De Marinis, Filippo ^c  

^a S G MOSCATI HOSPITAL   (Italy)

^b Roche   (Italy)

^c SAN CAMILLO FORLANINI HOSPITAL   (Italy)

Author keywords

Chemotherapy; Epidermal growth factor receptor; Intermittent therapy; Targeted therapy; Tyrosine kinase inhibitors

Indexed keywords

DOCETAXEL; EPIDERMAL GROWTH FACTOR RECEPTOR; ERLOTINIB; K RAS PROTEIN;

ADULT; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CANCER SURVIVAL; DIARRHEA; DRUG MECHANISM; DRUG TOLERABILITY; FEMALE; GENE MUTATION; HUMAN; LUNG NON SMALL CELL CANCER; LUNG SQUAMOUS CELL CARCINOMA; MAJOR CLINICAL STUDY; MALE; MULTIPLE CYCLE TREATMENT; NEUTROPENIA; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL; PROGRESSION FREE SURVIVAL; RANDOMIZED CONTROLLED TRIAL; RASH; RECURRENT CANCER; RECURRENT SQUAMOUS NON SMALL CELL LUNG CANCER; TREATMENT PLANNING;

EID: 79551512157     PISSN: 15257304     EISSN: 19380690     Source Type: Journal    
DOI: 10.1016/j.cllc.2011.05.003     Document Type: Erratum

References (17)

1. Socinski MA, Crowell R, Hensing TE, et al. Treatment of non-small cell lung cancer, stage IV - ACCP evidence-based clinical practice guidelines (2nd Edition). Chest 2007;132:277S-89S.
2. D'Addario G, Felip E. Non-small-cell lung cancer: ESMO clinical recommendations for diagnosis, treatment and follow-up. Ann Oncol 2009;20(suppl 4): iv68-70.
3. Azzoli CG, Baker S, Jr, Temin S, et al. American Society of Clinical Oncology Clinical Practice Guideline Update on Chemotherapy for Stage IV Non-Small-Cell Lung Cancer. J Clin Oncol 2009;27:6251-66.
4. Gatzemeier U, Pluzanska A, Szczesna A, et al. Phase III study of erlotinib in combination with cisplatin and gemcitabine in advanced non-small cell lung cancer (NSCLC): the Tarceva Lung Cancer Investigation Trial. J Clin Oncol 2007;25:1545-52.
5. Herbst RS, Prager D, Hermann R, et al. TRIBUTE: a phase III trial of erlotinib hydrochloride (OSI-774) combined with carboplatin and paclitaxel chemotherapy in advanced non-small-cell lung cancer. J Clin Oncol 2005;23:5892-9.
6. Shepherd FA, Perira JR, Ciuleanu T, et al. Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med 2005;353:123-32.
7. Clark GM, Zborowski DM, Sanatabarbara P, et al. Smoking history and epidermal growth factor receptor expression as predictors of survival benefit from erlo-tinib for patients with non-small-cell lung cancer in the National Cancer Institute of Canada Clinical Trials Group study BR.21. Clin Lung Cancer 2006;7:389-94.
8. Tracy S, Mukohara T, Hansen M, et al. Gefitinib induces apoptosis in the EG-FRL858R non-small-cell lung cancer cell line H3255. Cancer Res 2004;64:7241-4.
9. Mahaffey CM, Davies AM, Lara PN, Jr, et al. Schedule-dependent apoptosis in K-ras mutant non-small-cell lung cancer cell lines treated with docetaxel and erlo-tinib: rationale for pharmacodynamic separation. Clin Lung Cancer 2007;8:548-53.
10. Solit DB, She Y, Moasser M, et al. Pulsatile administration of the epidermal growth factor receptor inhibitor gefitinib is significantly more effective than continuous dosing for sensitizing tumors to paclitaxel. Clin Cancer Res 2005;11:1983-9.
11. Mok TS, Wu YL, Yu CJ, et al. Randomized, placebo-controlled, phase II study of sequential erlotinib and chemotherapy as first-line treatment for advanced non-small-cell lung cancer. J Clin Oncol 2009;27:5080-7.
12. Riely GJ, Rivzi NA, Kris MG, et al. Randomized phase II study of pulse erlotinib before or after carboplatin and paclitaxel in current or former smokers with advanced non-small-cell lung cancer. J Clin Oncol 2009;27:264-70.
13. Davies AM, Hesketh PJ, Beckett L, et al. Pharmacodynamic separation of erlo-tinib and docetaxel (DOC) in advanced non-small cell lung cancer (NSCLC): Overcoming hypothesized antagonism. J Clin Oncol 2007;25(18 suppl): 413s (abstract 7618).
14. Davies AM, Ho C, Beckett L, et al. Intermittent erlotinib in combination with pemetrexed: phase I schedules designed to achieve pharmacodynamic separation. J Thorac Oncol 2009;4:862-8.
15. Li T, Gucalp R, Piperdi B, et al. Pharmacodynamic separation (PDS) of pemetrexed and erlotinib versus pemetrexed monotherapy as second-line therapy in patients with advanced non-small cell lung cancer (NSCLC): first stage analysis of a randomized phase II study. J Thorac Oncol 2009;4(1 suppl): S304-S305 (abstract A6.2).
16. Hanna N, Shepherd FA, Fossella FV, et al. Randomized phase III trial of peme-trexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy. J Clin Oncol 2004;22:1589-97.
17. Lenth RV. Statistical power calculations. J Anim Sci 2007;85(suppl): E24-9.